PL373679A1 - Sposoby otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu - Google Patents

Sposoby otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu

Info

Publication number
PL373679A1
PL373679A1 PL03373679A PL37367903A PL373679A1 PL 373679 A1 PL373679 A1 PL 373679A1 PL 03373679 A PL03373679 A PL 03373679A PL 37367903 A PL37367903 A PL 37367903A PL 373679 A1 PL373679 A1 PL 373679A1
Authority
PL
Poland
Prior art keywords
amino
cyanoethenyl
benzonitrile
dimethylphenyl
pyrimidinyl
Prior art date
Application number
PL03373679A
Other languages
English (en)
Other versions
PL208533B1 (pl
Inventor
Didier Philippe Robert Schils
Joannes Josephus Maria Willems
Bart Petrus Anna Maria Jozef Medaer
Elisabeth Therese Jeanne Pasquier
Paul Adriaan Jan Janssen
Jan Heeres
Ruben Gerardus George Leenders
Jerome Emile Georges Guillemont
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31725448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373679(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL373679A1 publication Critical patent/PL373679A1/pl
Publication of PL208533B1 publication Critical patent/PL208533B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/20—Preparation of carboxylic acid nitriles by dehydration of carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL373679A 2002-08-09 2003-08-07 Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego PL208533B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078306 2002-08-09

Publications (2)

Publication Number Publication Date
PL373679A1 true PL373679A1 (pl) 2005-09-05
PL208533B1 PL208533B1 (pl) 2011-05-31

Family

ID=31725448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373679A PL208533B1 (pl) 2002-08-09 2003-08-07 Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego

Country Status (25)

Country Link
US (3) US7399856B2 (pl)
EP (1) EP1529032B1 (pl)
JP (1) JP4822707B2 (pl)
KR (2) KR101086678B1 (pl)
CN (4) CN102702111B (pl)
AR (1) AR040964A1 (pl)
AU (1) AU2003266413B2 (pl)
CA (2) CA2493794C (pl)
CL (1) CL2010000284A1 (pl)
CY (1) CY1114428T1 (pl)
DK (1) DK1529032T3 (pl)
EA (1) EA007953B1 (pl)
ES (1) ES2422196T3 (pl)
HR (1) HRP20050104B1 (pl)
IL (1) IL166710A (pl)
IS (1) IS2980B (pl)
MX (1) MXPA05001541A (pl)
MY (1) MY144894A (pl)
NO (1) NO330013B1 (pl)
NZ (1) NZ538611A (pl)
PL (1) PL208533B1 (pl)
PT (1) PT1529032E (pl)
SI (1) SI1529032T1 (pl)
TW (1) TWI314146B (pl)
WO (1) WO2004016581A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
WO2005123662A1 (en) * 2004-06-18 2005-12-29 Janssen Pharmaceutica N.V. Modified heck reaction
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
MX2007002594A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
DK1632232T6 (da) * 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
US7314962B2 (en) * 2005-04-15 2008-01-01 E. I. Du Pont De Nemours & Co. Alkylation of aromatic compounds
ES2437202T3 (es) * 2005-05-26 2014-01-09 Janssen R&D Ireland Procedimiento para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)-amino]benzonitrilo
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US8426434B2 (en) * 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2643294B1 (en) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited An improved rilpivirine process
EP2702044B1 (en) 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
WO2013170421A1 (zh) * 2012-05-14 2013-11-21 上海迪赛诺药业有限公司 利匹韦林盐酸盐醇化物多晶型物及其制备方法
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
WO2014009968A2 (en) * 2012-07-12 2014-01-16 Hetero Research Foundation Process for rilpivirine using novel intermediate
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
RS65159B1 (sr) 2016-10-24 2024-02-29 Janssen Sciences Ireland Unlimited Co Disperzibilni sastavi
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
EP0002341B1 (en) 1977-11-28 1982-01-20 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
AU751573C (en) * 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
JP2000035628A (ja) 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7276510B2 (en) * 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CN1494528A (zh) 2001-03-02 2004-05-05 ʷ��˿�������ȳ�ķ���޹�˾ 作为逆转录酶抑制剂的二苯酮
ES2292753T4 (es) * 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL220850B1 (pl) * 2002-05-03 2016-01-29 Janssen Pharmaceutica Nv Kopolimer dwublokowy, kompozycja zawierająca składnik aktywny i jej zastosowanie oraz sposób jej wytwarzania
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Also Published As

Publication number Publication date
CN100554245C (zh) 2009-10-28
AU2003266413A1 (en) 2004-03-03
KR101086678B1 (ko) 2011-11-25
BR0313545B1 (pt) 2021-07-27
IS2980B (is) 2017-09-15
HK1081527A1 (en) 2006-05-19
MY144894A (en) 2011-11-30
IL166710A0 (en) 2006-01-15
CA2493794A1 (en) 2004-02-26
NO330013B1 (no) 2011-02-07
EP1529032A1 (en) 2005-05-11
IS7621A (is) 2004-12-29
AU2003266413B2 (en) 2009-04-02
HK1174922A1 (en) 2013-06-21
CA2686429A1 (en) 2004-02-26
EA200500325A1 (ru) 2005-06-30
PL208533B1 (pl) 2011-05-31
EA007953B1 (ru) 2007-02-27
CN102702111A (zh) 2012-10-03
TWI314146B (en) 2009-09-01
JP4822707B2 (ja) 2011-11-24
CA2686429C (en) 2010-11-16
CN101481356A (zh) 2009-07-15
JP2005537303A (ja) 2005-12-08
MXPA05001541A (es) 2005-04-19
US20070191407A1 (en) 2007-08-16
US7563922B2 (en) 2009-07-21
IL166710A (en) 2010-12-30
KR101140785B1 (ko) 2012-05-03
DK1529032T3 (da) 2013-07-08
HRP20050104B1 (hr) 2014-02-14
CN102702111B (zh) 2014-12-17
CA2493794C (en) 2010-05-25
US20080167464A1 (en) 2008-07-10
TW200418810A (en) 2004-10-01
SI1529032T1 (sl) 2013-08-30
KR20050040906A (ko) 2005-05-03
EP1529032B1 (en) 2013-04-24
HK1129671A1 (en) 2009-12-04
CN102225902A (zh) 2011-10-26
US7705148B2 (en) 2010-04-27
HRP20050104A2 (en) 2006-03-31
CY1114428T1 (el) 2016-08-31
BR0313545A (pt) 2005-07-12
KR20100127889A (ko) 2010-12-06
NO20050524L (no) 2005-02-01
PT1529032E (pt) 2013-07-11
WO2004016581A1 (en) 2004-02-26
US7399856B2 (en) 2008-07-15
CN102225902B (zh) 2013-04-24
US20060167253A1 (en) 2006-07-27
CL2010000284A1 (es) 2010-08-20
ES2422196T3 (es) 2013-09-09
AR040964A1 (es) 2005-04-27
HK1161869A1 (en) 2012-08-10
CN101481356B (zh) 2012-07-11
NZ538611A (en) 2007-03-30
CN1681774A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
IL166710A (en) Processes for the preparation of 4-[[4-[[-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
LTC1632232I2 (lt) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
IL202363A0 (en) Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NO2014032I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
HUP0500851A3 (en) Process for the preparation of rosuvastatin
PL363393A1 (pl) Nowe związki pirymidynowe
PT1578731E (pt) Processo para a preparação de compostos pirimidina
AP2296A (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
PL375263A1 (pl) 2,5-Podstawione pochodne pirymidyny jako antagoniści IX receptora CCR-3
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
GB0308892D0 (en) Process for the preparation of 2-[4-(4-flurophenyl)-5-12-(methylthio)-4-pyrimidinyl]-1H-imidazol-2yl]-5-me thyl-trans-1,3-dioxane-5-carboxylic acid
SI1490363T1 (sl) Postopki za pripravo 2-(7-kloro-1,8-naftiridin-2-il) -3-(5-metil-2-okso-heksil)-1-izoindolinona
GB0130695D0 (en) Pyrazola[4,3]pyrimidine

Legal Events

Date Code Title Description
RECP Rectifications of patent specification